ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
This Quarter Return
+12.77%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$616M
AUM Growth
+$616M
(+19%)
Cap. Flow
+$33.1M
Cap. Flow
% of AUM
5.37%
Top 10 Holdings %
Top 10 Hldgs %
49.49%
Holding
239
New
40
Increased
61
Reduced
56
Closed
33
Top Buys
| 1 |
Keros Therapeutics
KROS
|
$52.1M |
| 2 |
Prothena Corp
PRTA
|
$20.5M |
| 3 |
SPDR S&P 500 ETF Trust
SPY
|
$14M |
| 4 |
CytomX Therapeutics
CTMX
|
$6.89M |
| 5 |
ABVX
Abivax
ABVX
|
$6.59M |
Top Sells
| 1 |
RAPT Therapeutics
RAPT
|
$41.5M |
| 2 |
Roivant Sciences
ROIV
|
$17.4M |
| 3 |
SWTX
SpringWorks Therapeutics
SWTX
|
$8.63M |
| 4 |
Immunovant
IMVT
|
$6.94M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$6.34M |
Sector Composition
| 1 | Healthcare | 83.61% |
| 2 | Financials | 2.95% |
| 3 | Consumer Discretionary | 0% |
| 4 | Utilities | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Keros Therapeutics
KROS
$618M
| $71.9M | 11.03% | 5,389,264 +3,902,803 | +263% | +$52.1M |
|
2
Protagonist Therapeutics
PTGX
$3.67B
| $52.4M | 8.04% | 948,069 +8,400 | +0.9% | +$464K |
|
3
Alpha Architect 1-3 Month Box ETF
BOXX
$7.91B
| $38M | 5.83% | 337,125 | – | – |
|
4
Zai Lab
ZLAB
$3.68B
| $29.7M | 4.56% | 850,437 -90,421 | -10% | -$3.16M |
|
|
ABVX
5
Abivax
ABVX
$6.12B
| $23.5M | 3.6% | 3,071,340 +861,321 | +39% | +$6.59M |
|
|
6
Roivant Sciences
ROIV
$8.15B
| $21.9M | 3.35% | 1,940,797 -1,542,607 | -44% | -$17.4M |
|
|
7
Prothena Corp
PRTA
$441M
| $20.5M | 3.14% | +3,375,009 | New | +$20.5M |
|
8
Cytokinetics
CYTK
$4.23B
| $19.2M | 2.95% | 582,147 +191,418 | +49% | +$6.32M |
|
|
9
SPDR S&P 500 ETF Trust
SPY
$658B
| $14M | 2.15% | +22,684 | New | +$14M |
|
10
CG Oncology
CGON
$2.04B
| $13.6M | 2.09% | 523,216 +222,082 | +74% | +$5.77M |
|
11
SPDR Bloomberg 1-3 Month T-Bill ETF
BIL
$42.1B
| $12.4M | 1.91% | 135,585 | – | – |
|
12
BridgeBio Pharma
BBIO
$9.89B
| $11.2M | 1.72% | 259,659 -79,976 | -24% | -$3.45M |
|
13
Inhibikase Therapeutics
IKT
$134M
| $9.99M | 1.53% | 5,122,105 | – | – |
|
|
SEPN
14
Septerna, Inc. Common Stock
SEPN
$539M
| $8.96M | 1.37% | 847,227 +126,379 | +18% | +$1.34M |
|
15
Arbutus Biopharma
ABUS
$711M
| $8.73M | 1.34% | 2,825,773 +946,659 | +50% | +$2.93M |
|
16
89bio
ETNB
$1.34B
| $8.6M | 1.32% | 875,983 +71,763 | +9% | +$705K |
|
|
17
Immunovant
IMVT
$2.56B
| $8.56M | 1.31% | 535,066 -433,800 | -45% | -$6.94M |
|
18
Savara
SVRA
$567M
| $8.21M | 1.26% | 3,600,670 +2,240,379 | +165% | +$5.11M |
|
19
Xenon Pharmaceuticals
XENE
$2.98B
| $8.12M | 1.25% | 259,503 +131,955 | +103% | +$4.13M |
|
|
BIOA
20
BioAge Labs, Inc. Common Stock
BIOA
$177M
| $8M | 1.23% | 1,937,123 +966,023 | +99% | +$3.99M |
|
|
PCSC
21
Perceptive Capital Solutions Corp Class A Ordinary Shares
PCSC
$117M
| $7.97M | 1.22% | 750,000 | – | – |
|
22
Amylyx Pharmaceuticals
AMLX
$836M
| $7.72M | 1.18% | 1,205,101 -266,486 | -18% | -$1.71M |
|
|
23
CytomX Therapeutics
CTMX
$336M
| $6.99M | 1.07% | 3,081,414 +3,034,378 | +6,451% | +$6.89M |
|
24
Taysha Gene Therapies
TSHA
$797M
| $6.95M | 1.07% | 3,009,870 +1,943,561 | +182% | +$4.49M |
|
|
SAGE
25
DELISTED
Sage Therapeutics
SAGE
| $6.58M | 1.01% | 721,599 -20,896 | -3% | -$191K |
|